Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Xencor reports Q1 EPS (4c), consensus (67c) » 16:05
05/05/21
05/05
16:05
05/05/21
16:05
XNCR

Xencor

$40.65 /

-0.14 (-0.34%)

Reports Q1 revenue…

Reports Q1 revenue $34.0M, consensus $16.45M. Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations into 2024. Xencor expects to end 2021 with between $425 million and $475 million in cash, cash equivalents and marketable securities. "We continue to expand and mature our clinical portfolio of XmAb(R) drug candidates, recently initiating a Phase 1 study for our second cytokine program, XmAb564, a wholly owned IL-2-Fc fusion protein, in healthy volunteers. We engineered this molecule to preferentially activate regulatory T cells, an emerging mechanism for treating patients with autoimmune diseases," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "Additionally, at the AACR meeting, we presented preclinical data from multiple early-stage programs that highlight our protein engineering expertise with our third cytokine, a wholly owned IL-12-Fc fusion protein, as well as the potential of our CD28 platform and XmAb 2+1 bispecific antibody format. Looking ahead, we will continue to present maturing data from our clinical-stage programs, and we have plans to initiate several additional clinical studies this year and early 2022, including a Phase 2 study in prostate cancer with XmAb717, our PD-1 x CTLA-4 bispecific antibody."

ShowHide Related Items >><<
XNCR Xencor
$40.65 /

-0.14 (-0.34%)

XNCR Xencor
$40.65 /

-0.14 (-0.34%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
XNCR Xencor
$40.65 /

-0.14 (-0.34%)

Over a week ago
Hot Stocks
Xencor doses first subject in ph1 study of XmAb564 » 16:11
04/28/21
04/28
16:11
04/28/21
16:11
XNCR

Xencor

$44.03 /

+0.46 (+1.06%)

Xencor announced that the…

Xencor announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564, an engineered IL-2-Fc cytokine in development as a potential treatment for patients with autoimmune diseases. The study will evaluate the safety and tolerability of XmAb564, administered subcutaneously in healthy adult volunteers.

ShowHide Related Items >><<
XNCR Xencor
$44.03 /

+0.46 (+1.06%)

XNCR Xencor
$44.03 /

+0.46 (+1.06%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
XNCR Xencor
$44.03 /

+0.46 (+1.06%)

Conference/Events
Xencor management to meet virtually with Wedbush » 04:55
04/22/21
04/22
04:55
04/22/21
04:55
XNCR

Xencor

$42.16 /

+0.72 (+1.74%)

Virtual Meetings to be…

Virtual Meetings to be held April 21-22 hosted by Wedbush.

ShowHide Related Items >><<
XNCR Xencor
$42.16 /

+0.72 (+1.74%)

XNCR Xencor
$42.16 /

+0.72 (+1.74%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
XNCR Xencor
$42.16 /

+0.72 (+1.74%)

Conference/Events
Xencor management to meet virtually with Wedbush » 08:42
04/21/21
04/21
08:42
04/21/21
08:42
XNCR

Xencor

$41.55 /

-0.5 (-1.19%)

Virtual Meetings to be…

Virtual Meetings to be held April 21-22 hosted by Wedbush.

ShowHide Related Items >><<
XNCR Xencor
$41.55 /

-0.5 (-1.19%)

XNCR Xencor
$41.55 /

-0.5 (-1.19%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
XNCR Xencor
$41.55 /

-0.5 (-1.19%)

Hot Stocks
Xencor presents data from preclinical XmAb Bispecific antibody/cytokine programs » 15:34
04/11/21
04/11
15:34
04/11/21
15:34
XNCR

Xencor

$40.45 /

-1.07 (-2.58%)

Xencor announced the…

Xencor announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research Annual Meeting, being held virtually April 10-15, 2021. According to Abstract 1743, "IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents," IL-12 is a potent proinflammatory cytokine produced by activated antigen-presenting cells, and it leads to proliferation of T cells and NK cells and increased cytotoxicity through high levels of interferon gamma signaling. As a potent immune stimulating protein, IL-12 can have a significant effect on shrinking tumors; however, prior clinical studies have demonstrated it to have a narrow therapeutic window, limiting potential response rates. Xencor's IL-12-Fc cytokine program builds on the company's prior work with IL-15-Fc cytokines in oncology, where reduced potency led to improved pharmacokinetics, pharmacodynamics and tolerability in preclinical studies. IL-12-Fc fusions were engineered with reduced potency in order to improve potential tolerability, slow receptor-mediated clearance and prolong the molecules' half-lives, compared to native IL-12. The potency-reduced IL-12-Fc fusions demonstrated significant anti-tumor activity in vivo concurrent with activation and proliferation of CD8+ T cells and increased levels of interferon gamma in serum. In non-human primates, the engineered cytokines had an improved pharmacokinetic profile and therapeutic window compared to a native cytokine-Fc fusion, with superior exposure, a more gradual dose response and similar levels of cytokine production in serum. According to Abstract: 1880, "PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors," Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to tumor cells. PD-L1, which is expressed on many types of tumors, suppresses anti-tumor responses by the immune system and has been shown to directly inhibit CD28 co-stimulation. A PD-L1 x CD28 bispecific antibody, therefore, may promote CD28 co-stimulation and simultaneously block CD28's suppression by PD-L1. In vitro, the combination of the PD-L1 x CD28 and a CD3 T cell engager enhanced T cell activation and proliferation compared to the CD3 bispecific alone, as designed. PD-L1 x CD28 also enhanced the interaction between T cells and antigen presenting cells and exhibited strong CD28-dependent anti-tumor activity in mice. PD-L1 x CD28 was well tolerated in non-human primates and exhibited favorable pharmacokinetics. According to Abstract: 1860, "Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells," Claudin-6 is a tumor-associated antigen overexpressed in ovarian cancer and other solid tumors, and its differential expression in cancerous tissue makes CLDN6 an intriguing target for CD3 bispecific antibodies. Many members of the claudin family, which are small transmembrane proteins, have high sequence identity, which complicates selectivity among claudins. CLDN6 x CD3 bispecific antibodies were engineered in the XmAb 2+1 format, and the tumor binding domain was further engineered for improved selectivity of CLDN6 over similar claudin family members, such as CLDN9. In preclinical models, CLDN6 x CD3 bound more preferentially to tumor cells compared to cell lines with normal tissue CLDN9 expression levels. Lead candidates demonstrated reversal of tumor growth in human-cell engrafted mouse models of ovarian cancer. Further data from non-human primate studies demonstrated the candidates were well-tolerated with favorable pharmacokinetic profiles. According to Abstract: 1831, "Affinity tuned XmAb 2+1 GPC3 x CD3 bispecific antibodies demonstrate selective activity in liver cancer models," GPC3 is an antigen associated with hepatocellular carcinoma, squamous cell carcinoma of the lung and other cancers. Under certain conditions, GPC3 can trigger Wnt signaling and promote tumor proliferation. Despite a favorable expression profile, unfavorable tolerability has been reported from multiple clinical studies evaluating CAR-T therapy and T cell engaging bispecific antibodies that target GPC3. GPC3 x CD3 bispecific antibodies in the XmAb 2+1 format selectively recruited T cells to kill high GPC3-expressing cancer cells and avoided cytotoxicity to a low GP3C-expressing cell line. A comparison of GPC3 x CD3 bispecific antibodies with the XmAb 2+1 format and first-generation T cell engagers demonstrated similar anti-tumor activity and immune cell proliferation in vitro.

ShowHide Related Items >><<
XNCR Xencor
$40.45 /

-1.07 (-2.58%)

XNCR Xencor
$40.45 /

-1.07 (-2.58%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
XNCR Xencor
$40.45 /

-1.07 (-2.58%)

Over a month ago
Conference/Events
Barclays to hold a virtual conference » 10:06
03/10/21
03/10
10:06
03/10/21
10:06
FRLN

Freeline

$14.50 /

-0.04 (-0.28%)

, REGN

Regeneron

$470.59 /

-0.21 (-0.04%)

, ICLR

Icon

$181.51 /

+0.51 (+0.28%)

, CI

Cigna

$236.00 /

-0.91 (-0.38%)

, CLLS

Cellectis

$21.75 /

+ (+0.00%)

, PTCT

PTC Therapeutics

$59.18 /

+0.13 (+0.22%)

, THC

Tenet

$54.20 /

+0.26 (+0.48%)

, BKD

Brookdale Senior Living

$6.15 /

+0.12 (+1.99%)

, GOCO

GoHealth

$10.43 /

-0.05 (-0.48%)

, AXNX

Axonics

$56.98 /

+0.46 (+0.81%)

, GTS

Triple-S

$27.51 /

-0.04 (-0.15%)

, QDEL

Quidel

$160.76 /

+5.25 (+3.38%)

, LHCG

LHC Group

$182.36 /

-1.16 (-0.63%)

, KIN

Kindred Biosciences

$4.79 /

+0.11 (+2.35%)

, XNCR

Xencor

$44.78 /

+0.405 (+0.91%)

, TNDM

TNDM

/

+

, UHS

Universal Health

$132.13 /

+0.86 (+0.66%)

, AMRX

Amneal Pharmaceuticals

$6.09 /

+0.12 (+2.01%)

, RARE

Ultragenyx

$127.43 /

+3.15 (+2.53%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 will be held on March 8-11.

ShowHide Related Items >><<
XNCR Xencor
$44.78 /

+0.405 (+0.91%)

UHS Universal Health
$132.13 /

+0.86 (+0.66%)

TNDM TNDM
/

+

THC Tenet
$54.20 /

+0.26 (+0.48%)

REGN Regeneron
$470.59 /

-0.21 (-0.04%)

RARE Ultragenyx
$127.43 /

+3.15 (+2.53%)

QDEL Quidel
$160.76 /

+5.25 (+3.38%)

PTCT PTC Therapeutics
$59.18 /

+0.13 (+0.22%)

LHCG LHC Group
$182.36 /

-1.16 (-0.63%)

KIN Kindred Biosciences
$4.79 /

+0.11 (+2.35%)

ICLR Icon
$181.51 /

+0.51 (+0.28%)

GTS Triple-S
$27.51 /

-0.04 (-0.15%)

GOCO GoHealth
$10.43 /

-0.05 (-0.48%)

FRLN Freeline
$14.50 /

-0.04 (-0.28%)

CLLS Cellectis
$21.75 /

+ (+0.00%)

CI Cigna
$236.00 /

-0.91 (-0.38%)

BKD Brookdale Senior Living
$6.15 /

+0.12 (+1.99%)

AXNX Axonics
$56.98 /

+0.46 (+0.81%)

AMRX Amneal Pharmaceuticals
$6.09 /

+0.12 (+2.01%)

FRLN Freeline
$14.50 /

-0.04 (-0.28%)

03/01/21 Stifel
Freeline initiated with a Buy at Stifel
11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
09/01/20 Wedbush
Wedbush bullish on Freeline, initiates with an Outperform
REGN Regeneron
$470.59 /

-0.21 (-0.04%)

02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
02/08/21 SVB Leerink
Regeneron price target raised to $640 from $623 at SVB Leerink
02/08/21 Credit Suisse
Regeneron price target lowered to $753 from $758 at Credit Suisse
ICLR Icon
$181.51 /

+0.51 (+0.28%)

03/08/21 Baird
Baird upgrades Icon, disagrees with view that PRA deal 'destroys' value
03/08/21 KeyBanc
PRA Health downgraded to Sector Weight at KeyBanc
03/08/21 Baird
Icon upgraded to Outperform from Neutral at Baird
03/02/21 Barclays
PPD initiated with an Overweight at Barclays
CI Cigna
$236.00 /

-0.91 (-0.38%)

03/09/21 BMO Capital
Cigna price target raised to $290 from $270 at BMO Capital
03/09/21 Truist
Cigna price target raised to $280 from $260 at Truist
03/09/21 Mizuho
Cigna price target raised to $264 from $229 at Mizuho
03/03/21 Piper Sandler
Cigna acquisition 'incremental negative' for Hims & Hers, says Piper Sandler
CLLS Cellectis
$21.75 /

+ (+0.00%)

10/15/20 Baird
Cellectis downgraded to Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral from Outperform at Baird
08/19/20
Fly Intel: Top five analyst upgrades
08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
PTCT PTC Therapeutics
$59.18 /

+0.13 (+0.22%)

02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
01/05/21 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
THC Tenet
$54.20 /

+0.26 (+0.48%)

02/11/21 Credit Suisse
Tenet price target raised to $58 from $52 at Credit Suisse
02/11/21 Citi
Tenet price target raised to $58 from $50 at Citi
01/21/21 UBS
Tenet price target raised to $60 from $37 at UBS
01/14/21 Raymond James
Tenet price target raised to $60 from $55 at Raymond James
BKD Brookdale Senior Living
$6.15 /

+0.12 (+1.99%)

03/09/21 RBC Capital
Brookdale Senior Living price target raised to $7 from $4 at RBC Capital
01/11/21 BMO Capital
Brookdale data supports cautious view on senior housing, says BMO
12/02/20 Jefferies
Brookdale Senior Living downgraded to Hold following run-up at Jefferies
12/02/20 Jefferies
Brookdale Senior Living downgraded to Hold from Buy at Jefferies
GOCO GoHealth
$10.43 /

-0.05 (-0.48%)

11/12/20 Evercore ISI
GoHealth price target lowered to $25 from $27 at Evercore ISI
10/06/20 Credit Suisse
Walmart entry shows attractiveness of insurance market, says Credit Suisse
10/02/20 Raymond James
GoHealth initiated with an Outperform at Raymond James
08/14/20 Evercore ISI
GoHealth added to Tactical Outperform List at Evercore ISI
AXNX Axonics
$56.98 /

+0.46 (+0.81%)

03/03/21 Piper Sandler
Piper 'increasingly bullish' on Axonics after closer look at deal
01/26/21 Baird
Axonics price target raised to $65 from $58 at Baird
01/26/21 Piper Sandler
Axonics price target raised to $64 from $57 at Piper Sandler
01/07/21 Morgan Stanley
Axonics price target raised to $58 from $53 at Morgan Stanley
GTS Triple-S
$27.51 /

-0.04 (-0.15%)

QDEL Quidel
$160.76 /

+5.25 (+3.38%)

02/19/21 JPMorgan
Quidel price target lowered to $170 from $175 at JPMorgan
02/19/21 Piper Sandler
Quidel should be bought on QuickVue OTC delay, says Piper Sandler
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
LHCG LHC Group
$182.36 /

-1.16 (-0.63%)

02/08/21 Deutsche Bank
LHC Group price target raised to $260 from $240 at Deutsche Bank
01/25/21 Credit Suisse
LHC Group initiated with an Outperform at Credit Suisse
01/05/21 Truist
LHC Group price target raised to $260 from $245 at Truist
11/05/20 Oppenheimer
LHC Group price target raised to $250 from $245 at Oppenheimer
KIN Kindred Biosciences
$4.79 /

+0.11 (+2.35%)

12/24/20 Barclays
Kindred atopic dermatitis portfolio could net $130M in sales, says Barclays
12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
12/01/20 Alliance Global Partners
Kindred price target lowered to $10.25 from $12.50 at Alliance Global
XNCR Xencor
$44.78 /

+0.405 (+0.91%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
TNDM TNDM
/

+

02/25/21 Lake Street
Tandem Diabetes price target raised to $150 from $137 at Lake Street
02/04/21 Piper Sandler
Tandem trades at 'significant discount' to Insulet, says Piper Sandler
01/21/21 Citi
Citi adds Tandem, removes Guardant from 'Value Creators' list
12/15/20 Wells Fargo
Wells Fargo says Buy Inari Medical, Sell NuVasive in MedTech ratings shake-up
UHS Universal Health
$132.13 /

+0.86 (+0.66%)

03/02/21 Citi
Universal Health price target lowered to $151 from $162 at Citi
01/05/21 Deutsche Bank
Universal Health price target raised to $145 from $135 at Deutsche Bank
01/05/21 BofA
BofA sees tailwinds for healthcare facilities, names HCA Healthcare top pick
01/05/21 BofA
Universal Health downgraded to Underperform from Neutral at BofA
AMRX Amneal Pharmaceuticals
$6.09 /

+0.12 (+2.01%)

03/08/21 Goldman Sachs
Amneal Pharmaceuticals upgraded to Buy from Sell at Goldman Sachs
03/01/21 Barclays
Amneal Pharmaceuticals price target raised to $8 from $6 at Barclays
12/14/20 Guggenheim
Amneal Pharmaceuticals upgraded to Buy from Neutral at Guggenheim
12/14/20 Barclays
Amneal upgraded to Overweight on generic recovery at Barclays
RARE Ultragenyx
$127.43 /

+3.15 (+2.53%)

03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
02/12/21 JPMorgan
Ultragenyx downgraded to Neutral from Overweight at JPMorgan
XNCR Xencor
$44.78 /

+0.405 (+0.91%)

UHS Universal Health
$132.13 /

+0.86 (+0.66%)

TNDM TNDM
/

+

THC Tenet
$54.20 /

+0.26 (+0.48%)

REGN Regeneron
$470.59 /

-0.21 (-0.04%)

RARE Ultragenyx
$127.43 /

+3.15 (+2.53%)

QDEL Quidel
$160.76 /

+5.25 (+3.38%)

PTCT PTC Therapeutics
$59.18 /

+0.13 (+0.22%)

LHCG LHC Group
$182.36 /

-1.16 (-0.63%)

KIN Kindred Biosciences
$4.79 /

+0.11 (+2.35%)

ICLR Icon
$181.51 /

+0.51 (+0.28%)

GOCO GoHealth
$10.43 /

-0.05 (-0.48%)

CLLS Cellectis
$21.75 /

+ (+0.00%)

CI Cigna
$236.00 /

-0.91 (-0.38%)

BKD Brookdale Senior Living
$6.15 /

+0.12 (+1.99%)

AXNX Axonics
$56.98 /

+0.46 (+0.81%)

AMRX Amneal Pharmaceuticals
$6.09 /

+0.12 (+2.01%)

  • 16
    Dec
  • 29
    Oct
  • 07
    Aug
  • 15
    Jul
  • 27
    May
  • 08
    May
UHS Universal Health
$132.13 /

+0.86 (+0.66%)

THC Tenet
$54.20 /

+0.26 (+0.48%)

REGN Regeneron
$470.59 /

-0.21 (-0.04%)

QDEL Quidel
$160.76 /

+5.25 (+3.38%)

CI Cigna
$236.00 /

-0.91 (-0.38%)

UHS Universal Health
$132.13 /

+0.86 (+0.66%)

THC Tenet
$54.20 /

+0.26 (+0.48%)

REGN Regeneron
$470.59 /

-0.21 (-0.04%)

QDEL Quidel
$160.76 /

+5.25 (+3.38%)

PTCT PTC Therapeutics
$59.18 /

+0.13 (+0.22%)

ICLR Icon
$181.51 /

+0.51 (+0.28%)

GOCO GoHealth
$10.43 /

-0.05 (-0.48%)

CI Cigna
$236.00 /

-0.91 (-0.38%)

AXNX Axonics
$56.98 /

+0.46 (+0.81%)

REGN Regeneron
$470.59 /

-0.21 (-0.04%)

CI Cigna
$236.00 /

-0.91 (-0.38%)

BKD Brookdale Senior Living
$6.15 /

+0.12 (+1.99%)

Hot Stocks
Xencor, UCLA TDG collaborate to develop XmAb therapeutics » 05:12
02/25/21
02/25
05:12
02/25/21
05:12
XNCR

Xencor

$48.58 /

+0.09 (+0.19%)

Xencor and UCLA…

Xencor and UCLA Technology Development Group, or UCLA TDG, announced an agreement to develop novel therapeutic antibodies, pairing novel targets proposed by scientists at UCLA and utilizing Xencor's modular suite of XmAb technology platforms. Xencor and UCLA have established a streamlined framework to select promising biology, perform collaborative research and license intellectual property. Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures, such as bispecific antibodies and engineered cytokines, or amplification of natural immune functions, such as extending circulating half-life or enhancing immune cell cytotoxicity. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates for the treatment of patients with life-threatening and debilitating diseases. Two of these antibodies have been approved by the U.S. FDA, one for the treatment of patients with rare blood disorders and the other for an aggressive form of non-Hodgkin lymphoma. The UCLA Technology Development Group, the campus' gateway to innovation, research and entrepreneurship, will work with faculty to propose potential antibody drug candidates. For selected candidates, the collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements.

ShowHide Related Items >><<
XNCR Xencor
$48.58 /

+0.09 (+0.19%)

XNCR Xencor
$48.58 /

+0.09 (+0.19%)

02/24/21 Piper Sandler
Xencor remains a top pick for 2021 at Piper Sandler
02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
XNCR Xencor
$48.58 /

+0.09 (+0.19%)

Recommendations
Xencor remains a top pick for 2021 at Piper Sandler » 13:53
02/24/21
02/24
13:53
02/24/21
13:53
XNCR

Xencor

$48.64 /

+0.145 (+0.30%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Xencor with a $60 price target following the company's Q4 results. Xencor ended 2020 with cash of $604M and continues to escalate and expand the Phase I DUET-1 study of XmAb717, Tenthoff tells investors in a research note. The analyst sees continued development in neuroendocrine tumors, as well as merkel cell and small cell lung cancers, and says Xencor remains a top pick for 2021.

ShowHide Related Items >><<
XNCR Xencor
$48.64 /

+0.145 (+0.30%)

XNCR Xencor
$48.64 /

+0.145 (+0.30%)

02/24/21 RBC Capital
Xencor price target raised to $59 from $48 at RBC Capital
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
XNCR Xencor
$48.64 /

+0.145 (+0.30%)

Recommendations
Xencor price target raised to $59 from $48 at RBC Capital » 08:39
02/24/21
02/24
08:39
02/24/21
08:39
XNCR

Xencor

$48.46 /

-0.69 (-1.40%)

RBC Capital analyst…

RBC Capital analyst Gregory Renza raised the firm's price target on Xencor to $59 from $48 and keeps an Outperform rating on the shares after its Q4 earnings and liquidity update. The company is following a data-oriented development strategy, and he expects several data updates and trial initiations from its pipeline, which should drive a steady value appreciation in Xencor shares over the year, the analyst tells investors in a research note.

ShowHide Related Items >><<
XNCR Xencor
$48.46 /

-0.69 (-1.40%)

XNCR Xencor
$48.46 /

-0.69 (-1.40%)

02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
12/22/20 Piper Sandler
Xencor named a top pick for 2021 at Piper Sandler
XNCR Xencor
$48.46 /

-0.69 (-1.40%)

Upgrade
Xencor upgraded to Outperform from Market Perform at Raymond James » 07:33
02/24/21
02/24
07:33
02/24/21
07:33
XNCR

Xencor

$48.46 /

-0.69 (-1.40%)

Raymond James analyst…

Raymond James analyst Dane Leone upgraded Xencor (XNCR) to Outperform from Market Perform with a $58 price target. Leone believes a combination of plamotamab plus Monjuvi creates a direct commercial angle within an increasingly crowded field of CD20 bispecific antibodies and that the XmAb306 program in partnership with Genentech (RHHBY) is not currently reflected within valuation and could be nearing disclosure of initial clinical data during 2021, the analyst tells investors in a research note. Additionally, Leone thinks the validated protein engineering platform funded by royalties provides capital efficient optionality for earlier programs within oncology and immunology.

ShowHide Related Items >><<
XNCR Xencor
$48.46 /

-0.69 (-1.40%)

XNCR Xencor
$48.46 /

-0.69 (-1.40%)

02/24/21 Barclays
Xencor price target raised to $34 from $31 at Barclays
02/24/21 Raymond James
Xencor upgraded to Outperform from Market Perform at Raymond James
12/22/20 Piper Sandler
Xencor named a top pick for 2021 at Piper Sandler
11/16/20 Cantor Fitzgerald
Xencor price target raised to $56 from $40 at Cantor Fitzgerald
XNCR Xencor
$48.46 /

-0.69 (-1.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.